Transcriptions
Note: this content has been automatically generated.
00:00:00
in the rest of Europe to be honest I
00:00:13
think that problem is the data quality i
00:00:17
think that the data quality in large
00:00:19
databases to study I've shown from
00:00:21
England included more than 60,000
00:00:23
patients or per year and I think in a
00:00:27
very large database like we have the
00:00:29
problem our database lots of data are
00:00:31
missing and I think the data quality in
00:00:34
other countries or in other publications
00:00:37
might be not not as good as an hour
00:00:39
population and I think this might be a
00:00:43
reason why the data quality the recent
00:00:46
years is usually better than it was like
00:00:48
1995-96 or in this year's when we didn't
00:00:51
did not focus that much on the data
00:00:54
quality and large databases anything to
00:00:58
do with saturation levels because we
00:01:00
know that for example the UK they had
00:01:02
quite low saturation levels and most
00:01:05
units increase them now but higher
00:01:11
yeah maybe i'm not sure if this really
00:01:15
is the reason because if you look at the
00:01:19
data they already already started in God
00:01:21
increased in nineteen in 2005 and it was
00:01:25
usually time that point in time at least
00:01:28
in my experience when they increase in
00:01:31
situation is not already done it was
00:01:33
little later I think
00:01:49
and i would like to know you have been
00:01:56
comparing the treatment or the incidence
00:02:00
of treatment the treatment criteria the
00:02:02
same over Switzerland and England is it
00:02:04
the same basically saying yes it's
00:02:08
published very frequently and you know
00:02:12
the rapper upstages 125 there can define
00:02:15
quite clearly and it's pretty clear when
00:02:17
you have two should intervene introduced
00:02:20
to a treatment the problem the inner
00:02:23
study has shown is that in the beginning
00:02:25
there they had like cryotherapy and then
00:02:30
they moved to latest therapy and then
00:02:31
they moved to anti-vegf and so all the
00:02:34
data is little mixed and they just put
00:02:36
all this together in ROP treatment and
00:02:39
it's not really clear if it's really
00:02:41
isn't the same point in RP development
00:02:46
when they started the treatment so they
00:02:48
just mix it up but I think in general
00:02:50
the treatment criteria is basically the
00:02:53
same and in Europe in USA in Switzerland
00:02:57
do you do you change thank you for TSM
00:03:06
very important for TNT's nice
00:03:09
presentation is very short question do
00:03:11
you regard to your conclusions do you
00:03:15
adopt your management them based on oh
00:03:18
no no not yet so i think the results are
00:03:21
not reliable enough to adapt right now
00:03:23
that's what I think we should develop a
00:03:26
precise model already defined we want to
00:03:29
let's say below 30 weeks or between
00:03:31
below 29 weeks plus patients with
00:03:33
additional criteria like long oxygen
00:03:35
application and so on and then we have
00:03:37
to test this product respectively and we
00:03:40
said if we come up after let's say 2 35
00:03:43
years and say we really do not miss any
00:03:45
patients then I think we couldn't change
00:03:47
the recommendation but now I think it's